Verition Fund Management
IOVA icon

Verition Fund Management’s Iovance Biotherapeutics IOVA Stock Holding History

Verition Fund Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,583
Closed -$25.1K – 3882
2025
Q2 		$25.1K Sell
14,583
-31,568
-68% -$78.5K ﹤0.01% 3558
2025
Q1 		$154K Buy
46,151
+10,760
+30% +$55.5K ﹤0.01% 3101
2024
Q4 		$262K Buy
35,391
+11,712
+49% +$109K ﹤0.01% 2845
2024
Q3 		$222K Buy
+23,679
New +$224K ﹤0.01% 2818
2024
Q1 		– Sell
-20,149
Closed -$164K – 2869
2023
Q4 		$164K Buy
+20,149
New +$105K ﹤0.01% 2085
2023
Q2 		– Sell
-34,100
Closed -$208K – 2376
2023
Q1 		$208K Buy
+34,100
New +$235K ﹤0.01% 1745
2021
Q1 		– Sell
-20,742
Closed -$962K – 1645
2020
Q4 		$962K Sell
20,742
-14,914
-42% -$592K 0.01% 523
2020
Q3 		$1.17M Buy
35,656
+23,601
+196% +$724K 0.02% 345
2020
Q2 		$331K Buy
+12,055
New +$396K 0.01% 765

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Verition Fund Management's IOVA Position: Q3 2025 in Review

Verition Fund Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 14,583 shares — an estimated $25.1K sold.

Verition Fund Management first reported a position in IOVA in Q2 2020 and held it in 9 quarters. The position peaked at $1.17M in Q3 2020. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Verition Fund Management reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 14,583 Iovance Biotherapeutics shares in Q3 2025, an estimated $25.1K.
  • Verition Fund Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 9 quarters.
  • Verition Fund Management's Iovance Biotherapeutics position peaked at $1.17M in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.